Background: After a peak in the late 1980s, cancer mortality in Europe has declined by ∼10% in both sexes up to the early 2000s. We provide an up-to-date picture of patterns and trends in mortality from major cancers in Europe.
introduction After a peak in the late 1980s, cancer mortality in Europe has declined by ∼10% up to the early 2000s [1, 2] . The major components of these favorable trends in men were the fall in lung and other tobacco-related neoplasms, together with the persistent decline in gastric and a more recent decline in colorectal cancer mortality rates. In women, the major contributors were the persistent decline in cervical cancer and the favorable trends in breast and colorectal cancer mortality, particularly in northern and western Europe. Favorable trends were also observed for leukemias, Hodgkin lymphoma, testicular cancer, and a few other neoplasms amenable to treatment. We have predicted that most of these trends will be maintained up to the most recent years [3] .
There were, however, persistent marked differences in cancer mortality rates and trends within Europe, with generally less favorable trends in Russia, Romania, and other central and eastern European countries, compared with western Europe [1, 4] . These unfavorable trends were in part due to a greater smoking prevalence and other unfavorable lifestyle habits in this area of the continent, but also to some delays in effective disease management, including diagnosis and therapy [5] .
Monitoring of mortality patterns and trends is important for planning and evaluating programs for cancer control. Mortality is a synthetic and valid indicator which allows to assess the impact of preventive and therapeutic strategies against cancer. Moreover, it has long been available, reliable, and comparable across Europe. Thus, in order to provide an up-to-date picture of patterns and trends in mortality from major cancers in Europe, here we consider data for the quinquennium 2005-2009, together with an overview of trends since 1980.
materials and methods
We extracted official death certification numbers for 25 cancer sites in 34 European countries for the period 1980-2009 from the World Health Organization (WHO) database as available on electronic support [6] . The European Union (EU) was defined as the 27 member states as in January 2007, with the exclusion of Cyprus, for which data were available only for a limited number of years. Data for testicular and kidney cancer in Switzerland for the years 1995-2007 were provided by the Swiss National Institute for Cancer Epidemiology and Prevention [7] .
During the calendar period considered, three different revisions of the International Classification of Diseases (ICD) were used [8] [9] [10] . Classification of cancer deaths was re-coded, for all calendar periods and countries, according to the 10th revision of the ICD. Because the change from the 8th to the 10th revision of the ICD in 1995 in Switzerland caused discontinuities in trends, Swiss data for a few neoplasms (i.e. prostate, testis, bladder, and kidney) between 1980 and 1995 were corrected using age-specific factors [11] . To improve validity and comparability of data throughout different countries, we pooled together all intestinal sites (mainly colon and rectum), all uterine cancers (cervix and corpus), all skin neoplasms (including melanoma), all non-Hodgkin lymphoma, and all connective and soft tissue sarcomas. We did not consider long-term trends in pleural mesothelioma mortality, since pleural mesothelioma was not available separately from other pleural neoplams in the 9th revision of the ICD, and the combination of the 10th ICD codes C45.0 (mesothelioma) and C38.4 (other malignant neoplasms of the pleura) is influenced by misclassification with lung cancer, thus introducing spurious trends in several countries. Neoplasms of the brain or nerves were also not considered, since for several countries it was not possible to consistently pool together subsequent revisions of the ICD. Data for liver cancer-presented only in the tables-should be taken with due caution, due to the difficulty in distinguishing primary from unspecified liver cancers in several countries [12] .
In a few countries, mortality data were missing for one or more calendar years. No interpolation was made for missing data except for the definition of the EU rates, where, when data were not available for one or more years within a country, the nearest available data (i.e. generally that of the previous or subsequent year) were replicated.
We obtained estimates of the resident population, based on official censuses, from the same WHO database [6] . Population data for France in 2009 and for and Portugal and the UK in 2010 were obtained from the EUROSTAT database, since these data were not available in the WHO database [13] . From the matrices of certified deaths and resident populations, we computed age-specific rates for each 5-year age group (from 0-4 to 80-84, and ≥85 years) and calendar period. We then computed age-standardized rates per 100 000 person-years (at all ages and truncated 35-64 years) using the direct method and based on the world standard population [14] .
To identify significant changes in trends for the EU as a whole and 24 selected countries (excluding countries with less than 2 000 000 inhabitants and a few other entities such as Belarus, Belgium, Bulgaria, Croatia, Slovakia, because of difficulties in evaluating long-term trends), we carried out joinpoint regression analysis, which allows to identify the best-fitting points (the 'joinpoints') where a significant change in the linear slope (in a log scale) of the trend is detected [15, 16] . For each of the identified trends, we also computed the estimated annual percent change (APC) by fitting a regression line to the natural logarithm of the rates using calendar year as a regression variable.
results Table 1 gives the average annual number of deaths and the overall age-adjusted (world population) mortality rates from selected cancers per 100 000 men in 34 European countries plus the EU as a whole in [2005] [2006] [2007] [2008] [2009] . Male total cancer mortality rates in the EU were 153.6/100 000. The highest rates were in central and eastern European countries, including in particular Hungary (235.2/100 000), Croatia, Poland, and Baltic countries (around 200/100 000). In Russia, total cancer mortality in men was 184.0/100 000. The highest rates in western Europe were in France, Scotland, and Denmark (around 160/100 000); other major western European countries (Spain, Italy, the UK, and Germany) had rates between 138 and 152/100 000. The lowest rates (113 to 127/100 000) were in most Nordic countries and Switzerland. With reference to major cancer sites, male mortality rates across Europe ranged from 4.3 in Sweden to 24.6/100 000 in Russia for stomach cancer, from 11.2 in Greece to 33.0/100 000 in Hungary for intestinal cancer, from 6.0 in Portugal to 11.0/100 000 in Hungary for pancreatic cancer, from 19.3 in Sweden to 72.6/100 000 in Hungary for lung cancer, and from 8.9 in Italy to 20.8/100 000 in Estonia for prostate cancer. Table 2 gives corresponding figures in women. Total cancer mortality rate in EU women in 2005-2009 was 90.8/100 000. The range of variation was between 71.0/100 000 in Spain and 124.4 in Denmark, but there was no clear east-west gradient. Besides Denmark, female cancer mortality rates were over 100/ 100 000 in Hungary, Poland, Ireland, the Czech Republic, the Netherlands, and the UK. The lowest rates (below 85/100 000) were in Mediterranean countries, Finland, and Belarus. Rates ranged from 1.9 in France to 10.1/100 000 in Russia for stomach cancer, from 7.1 in Switzerland to 16.6/100 000 in Hungary for intestinal cancer, from 3.5 in Belarus to 30.1/100 000 in Scotland for lung cancer, from 12.7 in Spain to 21.3/100 000 in Denmark for breast cancer, and from 3.1 in Belarus to 7.2/100 000 in the Czech Republic for pancreatic cancer. while in Bulgaria and Romania, mortality has been leveling off over the last years only. In most countries, trends in total cancer mortality were more favorable in middle-aged populations. Cancer mortality has been converging in men and women from Mortality has been declining for cancer of the intestines (chiefly colon and rectum) since the early 1990s in most northern and western countries, including France, Germany, Italy, and the UK, as well as in the Czech Republic, which, however, started from exceedingly high rates (Figure 2) . Mortality from intestinal cancer has still been increasing or only leveling off over most recent calendar years, particularly in men, in some central and eastern European countries, such as Poland, Romania, and Russia, but also in Greece and Portugal, where rates were relatively low in the past. In most countries, mortality from intestinal cancer has been more favorable in women, with earlier and larger (proportional) declines.
Mortality from lung cancer in men has long been declining in Austria, Finland, the Netherlands, Switzerland, and the UK (Figure 2 ). Long-term declines in male lung cancer were observed in Sweden, too, where lung cancer has always been low. Male mortality rates had a peak in the mid/late 1980s in most other northern and western European countries and in the 1990s in several central and eastern countries, leveling off or declining thereafter. Only in Portugal and Romania, overall male lung cancer mortality was still increasing over recent years. Portuguese rates were, however, comparatively low (28.6/ 100 000). Overall and middle-age mortality from lung cancer in women increased up to recent calendar years in most European countries, the highest recent rises being in Hungary, France, and Spain. In contrast, in the Netherlands and the UK, which had high rates in the past, but also in Sweden, female lung cancer mortality has leveled off in the last few years, particularly in middle-aged women.
Mortality from breast cancer started to decline between the late 1980s and the early 1990s in most European countries, including those (Spain, Sweden, and Norway) that already had relatively low rates (below 20/100 000) in the 1990s (Figure 2) . The declines were generally more marked in relative terms in middle-aged women. Only in Bulgaria, Latvia, Russia, and Ukraine (which had comparatively low rates in the past) overall breast cancer rates have not declined in the last two decades, although trends were more favorable in the middle-aged. This led to a reduction of the difference in breast cancer mortality across Europe, most national overall rates being between 13 and 19/100 000 over most recent calendar years.
Mortality rates from prostate cancer have been leveling off since the mid-1990s in most countries of western Europe, including Italy, which had comparatively low rates in the past (Figure 2) . Declines in mortality rates have been observed more recently in the Czech Republic, Hungary, and Latvia, whereas mortality has still been rising over the most recent calendar years in other central and eastern European countries, including Poland, Romania, Russia, and Ukraine, which, however, maintained comparably low rates.
Supplementary Figure S1 , available at Annals of Oncology online, gives the corresponding trends for other selected cancer sites, i.e. oral cavity or pharynx, esophagus, stomach, gallbladder, pancreas, larynx, bone, connective and soft tissue sarcomas, skin, uterus, ovary, testis, bladder, kidney, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemias.
discussion
In the interpretation of the data presented, problems related to random variation, which are greater in relation to smaller populations and rarer cancers, should be considered. There are also problems of death certification reliability and accuracy (validity) due to the difficulties in ascertaining and certifying the cause of death for selected cancer sites [17, 18] . For some countries, coverage of the population is incomplete, and for that reason we excluded Albania, Macedonia, the Republic of Moldova, and several countries of the former Soviet Union whose national coverage was <90% [6] . Low-quality cause-ofdeath data have also been reported for some other countries, such as Greece, Bulgaria, and Poland [19] . However, for most countries considered, death certification is sufficiently reliable to permit meaningful inference on trends particularly for common cancer sites, including stomach, intestines, lung, and breast particularly under age 65 years. For a few cancer sites (including bone, soft tissue sarcomas, prostate, multiple myeloma, and other lymphoid neoplasms), diagnosis and certification may be influenced by the availability of diagnostic techniques and the accuracy of death certification.
This up-to-date analysis confirms the persistence of favorable trends in mortality from cancer in most European countries [3] . Total cancer mortality in EU men reached a peak at 187/ 100 000 in1988 to decline by 20% in 2009 (149.2) . Over the same calendar period, cancer mortality in women steadily declined by 16%, in the absence, however, of a peak in the late 1980s. Such a fall in cancer mortality in the EU was similar to that observed in the USA for women (−16% from 1991 to 2009), but it was smaller for men (−24%) [20] .
The major contributors to the decline in total cancer mortality in men were the steady fall in lung cancer and other tobacco-related neoplasms since the late 1980s, along with the persistent decline in gastric cancer mortality, and the decline since the early 1990s in mortality from cancers of the intestines and prostate. In women, the fall in total cancer mortality has been mainly due to the decline in intestinal and breast cancer mortality since the late 1980s and the long-term reduction in mortality from cancer of the (cervix) uterus. Only mortality from female lung cancer, pancreatic cancer, and soft tissue sarcomas in both sexes was still increasing (or not declining), while mortality from multiple myeloma has started to decline in the most recent calendar years.
Trends in cancer mortality have been less favorable in central and eastern European countries, where mortality (overall and from major sites) has been increasing up to the late 1990s/early 2000s. Consequently, over recent calendar years, there still was a twofold difference between the highest rate in male cancer mortality in Hungary (253.2/100 000) and the lowest one in Sweden (112.9/100 000), and a 1.7-fold one in women (between 124.4 in Denmark and 71.0/100 000 in Spain).
The favorable trends in cancer mortality can be largely attributed to favorable changes in the exposure to specific environmental and lifestyle risk factors [1, 2, 21] , mainly the reduction in tobacco consumption in subsequent generations of European men (with a favorable impact on lung and other tobacco-related neoplasms) [22, 23] , the reduction in occupational exposure to carcinogens (lung and bladder cancer) [24] , a better food conservation, and the control of Helicobacter pylori infection (gastric cancer) [25] , and a more affluent and varied diet (gastric, but probably colorectal cancer) [26] [27] [28] . Alcohol consumption has been steadily declining over the last decades in countries from southern Europe, with a consequent favorable impact on oral, pharyngeal, esophageal, and laryngeal cancers in those countries. Mortality from alcohol-related cancers remains, however, exceedingly high in countries from central and eastern Europe [22, 29] .
Early diagnosis through opportunistic and organized screenings has likely had a role on colorectal (through fecal occult blood test, flexible sigmoidoscopy, and colonoscopy) [28, 30] , breast (mammography) [31] [32] [33] , and possibly prostate cancer ( prostate-specific antigen test) mortality [34, 35] , although the quantification of the role of diagnostic screening Annals of Oncology original articles on mortality from those neoplasms (mostly for prostate cancer) is still under debate [32, [36] [37] [38] [39] [40] [41] . Screening has been the main responsible factor for the long-term decline in cervical cancer (through the PAP smear test and, more recently, the human papilloma virus test) particularly in countries from western and northern Europe [42] , while the less widespread and/or later adoption of cervical cancer screening in central and eastern countries is likely to largely explain the less favorable trends and the persistent exceedingly high rates in those countries [4, 43, 44] .
Improvements in disease treatment and management are likely to have appreciably contributed to the favorable trends in breast cancer (through hormonal therapies and chemotherapy, advancement in radiotherapy and surgery) [31, 33, 45] , but also colorectal (chemotherapy and radiotherapy) [28, 30] and prostate (androgen blockage, transurethral resection of the prostate, and radiotherapy) [35, 41] cancer. The adoption of newer therapies has also had a marked impact toward the reduction in mortality from a few other neoplasms amenable to treatment, including testicular cancer [35, 46] , Hodgkin lymphoma [47] , and leukemias [48] . Trends in mortality from those neoplasms have been less favorable in countries from central and eastern Europe, probably due to delays in the adoption of modern integrated therapies in those areas of the continent [5, 47] . With reference to testicular cancer, in several countries of western and northern Europe where treatments for this neoplasm (namely platinum-based therapies) have been available since the 1970s and where mortality from the disease has long been declining, a leveling off in the rates has been observed in most recent calendar years, suggesting that a plateau in mortality has been reached.
The persistent increase in mortality from lung cancer in women from most European countries reflects the different pattern of tobacco smoking in women when compared with men, with a later spread in tobacco consumption [21, 49] . The female lung cancer epidemic is still expanding in countries of western ( particularly France, Spain, and Switzerland) and central/eastern Europe, where smoking prevalence in women has only leveled off since the late 1990s, while the epidemic seems to have reached a plateau in the UK and the Netherlands, where smoking prevalence in women has been falling over the last few decades [50] . We predicted a persistent rise in lung cancer mortality in EU women, to reach a rate of 14.0/100 000 in 2015 [49] .
The reasons for the unfavorable patterns in pancreatic cancer in Europe (as in the USA and other developed countries of the world) are not clearly understood [51, 52] . Diagnostic improvements may partly or largely account for earlier rises. The reduction in male tobacco smoking prevalence (the major recognized risk factor for pancreatic cancer) [25] should have played a favorable role on mortality from this neoplasm. However, the increasing prevalence of overweight/obesity [53] and consequent type II diabetes-other two major recognized risk factors for pancreatic cancer [25] -over the last decades in many European countries have likely unfavorably influenced mortality from this neoplasm. Improved diagnosis and certification may also have contributed to the rising trends.
With the major exceptions of lung cancer in women and pancreatic cancer in both sexes, in the last quinquennium cancer mortality has declined moderately but steadily across Europe. There are, however, persisting differences across countries which require specific attention and intervention on risk factor control, early diagnosis, and improved management.
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